Zobrazeno 1 - 10
of 5 194
pro vyhledávání: ''
Autor:
Ryusaku Matsumoto, Masaaki Yamamoto, Genzo Iguchi, Shin Urai, Hidenori Fukuoka, Wataru Ogawa, Kentaro Suda, Hiroki Shichi, Keitaro Kanie, Yutaka Takahashi, Hironori Bando, Yasunori Fujita
Publikováno v:
Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors (ICIs) as a cancer immunotherapy have emerged as a treatment for multiple advanced cancer types. Because of enhanced immune responses, immune-related adverse events (irAEs), including endocrinopathies such as h
Autor:
Eva Karamitopoulou, Aurélie Pahud de Mortanges, Aurel Perren, Beat Gloor, Andreas Andreou, Marianne Tinguely
Publikováno v:
Cancer Immunology Research. 9:1439-1450
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). We examined the PD-1/PD-L1 expression and immunoarchitectural features by automated morphometric analysis using multiplex immunofluor
Publikováno v:
Turk J Gastroenterol
BACKGROUND: Considering the difficulty in predicting the biological behavior of gastrointestinal stromal tumors (GISTs) based on histological findings alone, genetic abnormalities have recently become an area of focus. Platelet-derived growth factor
Autor:
Atsushi Itou, Naoya Nakamura, Joaquim Carreras, Sawako Shiraiwa, Kiyoshi Ando, Sakura Tomita, Masashi Miyaoka, Haruka Ikoma, Yara Yukie Kikuti
Publikováno v:
Pathology International. 72:35-42
Diffuse large B-cell lymphoma with MYC rearrangement is defined as double/triple-hit lymphoma (DHL/THL) or single-hit lymphoma (SHL) by the inclusion of the BCL2 and BCL6 rearrangements status. DHL/THL is called as "high-grade B-cell lymphoma with MY
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8934-8943 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8934-8943 (2021)
Background Many real‐world studies of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are restricted to single centers, limiting the generalizability of their insights. This study aimed to identify important population‐based pre
Autor:
Yuan Wu, Chester Kao, Tian Zhang, Neal Ready, Michael B. Datto, Eric Powers, Jeffrey M. Clarke, John H. Strickler, Michelle F. Green
Publikováno v:
Clinical Lung Cancer. 22:500-509
Introduction A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembroliz
Autor:
Eiji Shinozaki, Hiroki Osumi, Mariko Ogura, Keisho Chin, Kensei Yamaguchi, Izuma Nakayama, Daisaku Kamiimabeppu, Takeru Wakatsuki, Keitaro Shimozaki, Daisuke Takahari, Akira Ooki
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8820-8828 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8820-8828 (2021)
Background Circulating tumor DNA (ctDNA) is a biomarker with potential to reflect comprehensive genomic information and overcome intratumor heterogeneity. In contrast, carcinoembryonic antigen (CEA) is a conventional tumor marker for predicting recur
Autor:
Julie Lynch, Kristine E. Lynch, Christy Morrissey, Danil V. Makarov, Daniel J. Becker, Michael J. Kelley, Scott E. Sherman, Steve Y. Lee, Kyung Min Lee
Publikováno v:
JCO Precis Oncol
PURPOSEAdvances in precision oncology, including RAS testing to predict response to epidermal growth factor receptor monoclonal antibodies (EGFR mAbs) in colorectal cancer (CRC), can extend patients’ lives. We evaluated uptake and clinical use of K
Autor:
Steven Kao, Tessa A. Morris, Mark Voskoboynik, Benjamin Solomon, Luke McLean, Wasek Faisal, Ross Jennens, Sagun Parakh, Craig R. Lewis, Malinda Itchins, Adam R. Broad, Melvin Chin
Publikováno v:
JCO Precision Oncology. :561-568
PURPOSE Leptomeningeal disease (LMD) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma is associated with a poor prognosis and limited treatment options. Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor with
Autor:
Takaaki Tokito, Akihiro Bessho, Satoshi Igawa, Shinji Sasada, Nobuhiko Seki, Naoki Furuya, Yosuke Tanaka, Koichi Minato, Kaoru Kubota, Hideki Hayashi, Hirotoshi Iihara, Rintaro Noro, Takayuki Kaburagi, Tsuneo Shimokawa, Hiroaki Okamoto, Masanao Nakashima, Shingo Miyamoto, T. Hirose, Toshiyuki Harada
Publikováno v:
Lung Cancer. 161:49-54
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity associated with this agent often leads to dose modifications. The aim